The FDA has issued AstraZeneca's least favorite form of draft guidance--the kind that helps other drugmakers develop copies of a blockbuster seller.
AstraZeneca CEO Pascal Soriot made it clear back in early 2014 that he planned to spin off a big chunk of the company's anti-infectives pipeline along with the neurosciences side of R&D. And now more than a year later the pharma company has completed the task, hatcheting down a once large group of researchers and birthing a small biotech with its own pipeline of antibiotics and a core group of investigators.
We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.
What's in the water at AstraZeneca? Maybe it's an elixir for top managers who want to run a smaller drugmaker. Maybe it's an anti-Big Pharma potion. Either way, it means a second high-level exec has left the U.K.-based drugmaker for a CEO post elsewhere.
AstraZeneca has lost its second top executive in less than two weeks, as VP James Ward-Lilley bids goodbye to Big Pharma to run the respiratory specialist Vectura--which happens to have partnerships with AZ lung-drug rivals GlaxoSmithKline and Novartis.
Growth in emerging markets may be slowing, but pharma sales there are still outpacing those everywhere else. And if recent numbers are any indication, AstraZeneca is topping its rivals for emerging markets expansion.
AstraZeneca and its agency DigitasLBI won the top award for pharma at the Cannes' Lions Health awards, for its disease awareness campaign "Take it From a Fish" about the importance of triglycerides. It was the first time a top award was given in pharma, as last year's judges did not select a Pharma Grand Prix winner.
FierceBiotech Radio is back with a two-part special from the BIO conference in Philadelphia.
At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.
Last week, the National Academies' Institute of Medicine hosted a two-day conference in Washington, DC, to promote the field of "comparative oncology"--translational research in pet dogs and cats that develop cancer naturally and therefore can provide important clues to aid human drug development. The event featured more than two dozen veterinarians and scientists, who covered a range of topics, from canine tumor genetics to appropriate trial design for veterinary clinical trials.